Boston, MA -- (SBWIRE) -- 12/10/2015 -- India's pricing regi me will continue to weigh on its pharmaceutical sector's growth potential. Affecting both local and multinational pharmaceutical firms, the price cuts can be substantial, thereby compounding the uncertainty created, especially as the decision process is carried out with limited consultation with the industry. Risks will also become more acute as the government looks to reform the pricing regime following the Supreme Court's verdict that existing prices are set at unreasonably high levels.

Headline Expenditure Projections

Pharmaceuticals: INR954bn (USD16bn) in 2014 to INR1,066bn (16bn) by 2015; +11.7% in local currency terms and 4.9% in US dollar terms.
Healthcare: INR5,085bn (USD83bn) in 2014 to INR5,716bn (USD88bn) by 2015; +12.4% in local currency terms and 5.6% in US dollar terms.

Get More Details on this Report and a Full Table of Contents at India Pharmaceuticals & Healthcare Report Q1 2016

Risk/Reward Index

India's pharmaceutical market is the ranks as the tenth most attractive amongst 19 other countries in the Asia Pacific region. India has one of the largest pharmaceutical markets in Asia but per capita pharmaceutical spending remains low which will limit the rewards for drugmakers. Furthermore, India's IP laws leave a lot to be desired despite the country signing the WTO's Agreement Trade-Related Aspects of Intellectual Property Rights (TRIPS). Nevertheless, approval times are shortening, with some innovative products being introduced in a relatively short period after mature market launch

The India Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's India Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the India pharmaceutical and healthcare industry.

Key Benefits

-Benchmark BMI's pharmaceutical and healthcare market forecasts for India, to test other views - a key input for successful budgeting and strategic business planning in the Indian pharmaceutical and healthcare market.
-Target business opportunities and risks in the Indian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in India.
-Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI?s forecast analysis, and taken together with BMI?s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

-Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ?000 population).
-Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
-Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
-Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
-OTC Drug Market: OTC sales (USDbn & % of total sales).
-Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI?s Pharmaceuticals and Healthcare Risk Reward Index

BMI?s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market?s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

-Kenya Pharmaceuticals & Healthcare Report Q1 2016
-Ukraine Pharmaceuticals & Healthcare Report Q1 2016
-Thailand Pharmaceuticals & Healthcare Report Q1 2016
-Kuwait Pharmaceuticals & Healthcare Report Q1 2016
-Pakistan Pharmaceuticals & Healthcare Report Q1 2016